Literature DB >> 34406244

Transcutaneous Electric Nerve Stimulation on ischemic rest pain in inpatients: randomised trial.

Patric Emerson Oliveira Gonçalves1, Matheus Milanez1, Ronald Luiz Gomes Flumignan2, Jorge Machado3, Tulio Pinho Navarro4, Ligia de Loiola Cisneros1.   

Abstract

OBJECTIVE: To investigate the efficacy of a short-term application of Transcutaneous Electric Nerve Stimulation to relieve rest pain in patients with chronic limb-threatening ischemia.
METHODS: In patients ³18 years old, with chronic limb-threatening ischemia and rest pain ³3 in the Visual Analogue Scale, without diabetic neuropathy were randomly assigned to 1) Transcutaneous Electric Nerve Stimulation (100 Hz, 200 μs) or 2) sham intervention, both during one or two 20 min treatment sessions. The primary outcome was pain intensity, assessed by the visual analogue scale (0-10 cm) and described by the McGill Pain Questionnaire. We used a t-test for difference of means.
RESULTS: A total of 169 patients were assessed, 23 met the study criteria and were randomized. Thirty-four applications were performed in two days: in the 17 Transcutaneous Nerve Stimulation and 17 sham. The within-group analysis indicated a pain decrease in both groups (Transcutaneous Electric Nerve Stimulation, from 7-3.9 cm, p<0.0001, and sham from 5.8-3.2 cm, p<0.0001). No statistically significant difference was verified between-groups (p=0.5).
CONCLUSIONS: Both groups showed a decrease in rest pain of 54 and 55%, respectively. However, there was no difference between short-term high-frequency Transcutaneous Electric Nerve Stimulation and sham intervention to relieve ischemic rest pain in chronic limb-threatening ischemia patients.

Entities:  

Mesh:

Year:  2021        PMID: 34406244     DOI: 10.1590/1806-9282.67.02.20200535

Source DB:  PubMed          Journal:  Rev Assoc Med Bras (1992)        ISSN: 0104-4230            Impact factor:   1.209


  1 in total

1.  The Potential of Electrical Stimulation and Smart Textiles for Patients with Diabetes Mellitus.

Authors:  Babette Engler; Sergey Tselmin; Doreen Ziehl; Ingo Weigmann; Andreas Birkenfeld; Stefan R Bornstein; Andreas Barthel; Tina Drechsel; Claudio Zippenfennig; Thomas Milani; Nikolaos Perakakis
Journal:  Horm Metab Res       Date:  2022-07-06       Impact factor: 2.788

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.